Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review
- PMID: 25846833
- DOI: 10.1007/s10067-015-2928-8
Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review
Abstract
The objective of this study was to report the clinical course of a cohort of patients with clinically amyopathic dermatomyositis (CADM) in correlation to the presence or absence of anti-melanoma differentiation-associated gene 5 (MDA-5) antibody. Five patients with CADM presented to our rheumatology unit between September 1, 2011 and March 31, 2014. We hereby present their clinical course, laboratory findings, imaging modalities, functional tests, and treatments regimens. Our cohort included five patients, with a mean age of 41.8 ± 17.7. Three patients, all anti-MDA-5 antibody positive, developed rapidly progressive interstitial lung disease (ILD) within 4.3 ± 4.5 months of presentation. Two of these patients succumbed to their disease within 30 months of diagnosis despite intensive immunosuppressive therapy. The third anti-MDA-5-positive patient with ILD is still stable, 20 months from disease onset, on massive combination therapy. One patient developed CADM associated with the anti-p155/140 antibody, a year after completing chemotherapy for non-seminomatous germ cell tumor. He presented with a benign clinical course with no evidence of ILD and no recurrence of malignancy after 20 months of follow-up. The fifth patient in our cohort, who is anti-MDA-5 negative and has no evidence of malignancy, also enjoys a benign clinical course. The presence of anti-MDA-5 antibodies in CADM patients is associated with rapidly progressive ILD and a poor prognosis. The serologic profile of patients with CADM should be routinely evaluated and integrated with clinical data in the management of these patients.
Keywords: Amyopathic dermatomyositis; Anti-melanoma differentiation-associated gene 5 antibody; Autoantibodies; Interstitial lung disease.
Similar articles
-
Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.Arthritis Care Res (Hoboken). 2016 May;68(5):689-94. doi: 10.1002/acr.22728. Arthritis Care Res (Hoboken). 2016. PMID: 26414240 Free PMC article.
-
Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.Respir Med. 2018 Jul;140:1-5. doi: 10.1016/j.rmed.2018.05.010. Epub 2018 May 22. Respir Med. 2018. PMID: 29957268
-
Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?BMC Pulm Med. 2015 Dec 9;15:159. doi: 10.1186/s12890-015-0154-4. BMC Pulm Med. 2015. PMID: 26651481 Free PMC article.
-
Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.Semin Arthritis Rheum. 2022 Apr;53:151959. doi: 10.1016/j.semarthrit.2022.151959. Epub 2022 Jan 31. Semin Arthritis Rheum. 2022. PMID: 35134633 Review.
-
Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.Rheumatol Int. 2018 Jul;38(7):1293-1296. doi: 10.1007/s00296-018-3991-7. Epub 2018 Feb 7. Rheumatol Int. 2018. PMID: 29417209 Free PMC article. Review.
Cited by
-
Livedo Racemosa, Reticulated Ulcerations, Panniculitis and Violaceous Plaques in a 46-year-old Woman.Indian Dermatol Online J. 2018 Jan-Feb;9(1):47-49. doi: 10.4103/idoj.IDOJ_72_17. Indian Dermatol Online J. 2018. PMID: 29441299 Free PMC article.
-
Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis.Clin Rheumatol. 2020 Jun;39(6):1919-1927. doi: 10.1007/s10067-019-04918-2. Epub 2020 Jan 15. Clin Rheumatol. 2020. PMID: 31942657
-
Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.J Clin Lab Anal. 2019 Oct;33(8):e22978. doi: 10.1002/jcla.22978. Epub 2019 Jul 13. J Clin Lab Anal. 2019. PMID: 31301087 Free PMC article.
-
Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review.Case Rep Rheumatol. 2017;2017:5386797. doi: 10.1155/2017/5386797. Epub 2017 Oct 31. Case Rep Rheumatol. 2017. PMID: 29225988 Free PMC article.
-
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.Clin Rheumatol. 2017 Aug;36(8):1919-1926. doi: 10.1007/s10067-017-3671-0. Epub 2017 May 9. Clin Rheumatol. 2017. PMID: 28488124 Review.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical